.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 6,384,077

« Back to Dashboard

Details for Patent: 6,384,077

Title: Highly purified EPA for treatment of schizophrenia and related disorders
Abstract:A pharmaceutical preparation comprising EPA in an appropriately assimilable form where of all the fatty acids present in the preparation at least 90%, and preferably at least 95%, is in the form of EPA and where less than 5%, and preferably less than 3%, is in the form of DHA is provided for the treatment of a psychiatric or central nervous disorder. The preparation may be administered with conventional drugs to treat psychiatric or central nervous disorders to improve their efficacy or reduce their side effects.
Inventor(s): Peet; Malcolm (Sheffield, GB), Vaddadi; Krishna S (Melbourne, AU)
Assignee: Laxdale Limited (Stirling, GB)
Filing Date:Jan 27, 2000
Application Number:09/492,741
Claims:1. A method of treating schizophrenia, a schizoaffective disorder, or a schizotypal disorder in a subject comprising administering to the subject a pharmaceutical preparation comprising EPA in an appropriately assimilable form, wherein of all the fatty acids present in the preparation at least 90% is in the form of EPA, and wherein less than 5% is in the form of docosahexaenoic acid (DHA), in conjunction with a drug which acts primarily on neurotransmitter metabolism or receptors.

2. The method of claim 1, wherein the drug is administered as a separate formulation.

3. The method of claim 1, wherein the drug is administered as part of the pharmaceutical preparation.

4. The method of claim 1, wherein the drug is clozapine.

5. The method of claim 1, wherein the drug is a typical or an atypical neuroleptic.

6. The method of claim 5, wherein the drug is chlorpromazine, haloperidol, risperidone, olanzapine, sertindole, ziprasidone, zotepine or amisulpiride.

7. The method of claim 1, wherein of all the fatty acids present in the preparation at least 95% is in the form of EPA.

8. The method of claim 1, wherein of all the fatty acids present in the preparation less than 3% is in the form of docosahexaenoic acid (DHA).

9. The method of claim 1, wherein among the other fatty acids present there are less than 5% of each of AA or DPA-n-3, individually.

10. The method of claim 1, wherein among the other fatty acids present there are less than 3% of each of AA or DPA-n-3, individually.

11. The method of claim 1, wherein the aggregate DHA, AA and/or DPA-n-3 content is less than 10% of the total fatty acids present.

12. The method of claim 1, wherein the aggregate DHA, AA and/or DPA-n-3 content is less than 5% of the total fatty acids present.

13. The method of claim 1, wherein the EPA is selected from the group consisting of: ethyl-EPA; lithium EPA; mono-, di- or triglyceride EPA; an ester or a salt of EPA; a free acid form of EPA; and an appropriate bioavailable EPA derivative which raises EPA levels in the subject.

14. A method of treating schizophrenia, a schizoaffective disorder, or a schizotypal disorder in a subject comprising administering to the subject a pharmaceutical preparation comprising EPA in an appropriately assimilable form, wherein of all the fatty acids present in the preparation at least 90% is in the form of EPA, and wherein less than 5% is in the form of docosahexaenoic acid (DHA).

15. The method of claim 14, wherein of all the fatty acids present in the preparation at least 95% is in the form of EPA.

16. The method of claim 14, wherein of all the fatty acids present in the preparation less than 3% is in the form of docosahexaenoic acid (DHA).

17. The method of claim 14, wherein among the other fatty acids present there are less than 5% of each of AA or DPA-n-3, individually.

18. The method of claim 14, wherein among the other fatty acids present there are less than 3% of each of AA or DPA-n-3, individually.

19. The method of claim 14, wherein the aggregate DHA, AA and/or DPA-n-3 content is less than 10% of the total fatty acids present.

20. The method of claim 14, wherein the aggregate DHA, AA and/or DPA-n-3 content is less than 5% of the total fatty acids present.

21. The method of claim 14, wherein the EPA is selected from the group consisting of: ethyl-EPA; lithium EPA; mono-, di- or triglyceride EPA; an ester or a salt of EPA; a free acid form of EPA; and an appropriate bioavailable EPA derivative which raises EPA levels in the subject.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc